Background: Factors that influence smoking initiation and age of smoking onset are important considerations in tobacco control. We evaluated European Union (EU)-wide differences in the age of onset of regular smoking, and the potential role of peer, parental and tobacco product design features on the earlier onset of regular smoking among adults <40 years old in 27 EU countries.
Methods: We analysed data from 4442 current and former smokers aged 15-39 years, collected for the Eurobarometer 77.1 survey (2012). Respondents reported their age at regular smoking onset and factors that influenced their decision to start smoking, including peer influence, parental influence and features of tobacco products. Multi-variable logistic regression, adjusted for age; geographic region; education; difficulty to pay bills; and gender, was used to assess the role of the various pro-tobacco influences on early onset of regular smoking (i.e. <18 years).
Results: Among ever smokers, the mean age of onset of regular smoking was 16.6 years, ranging from 15.8 to 18.8 years in member countries. 68.1% responded that they started smoking regularly when they were <18 years old. Ever smokers who reported they were influenced by peers (OR = 1.70; 95%CI 1.30-2.20) or parents (OR = 1.60; 95%CI 1.21-2.12) were more likely to have started smoking regularly <18 years old. No significant association between design and marketing features of tobacco products and an early initiation of regular smoking was observed (OR = 1.04; 95%CI 0.83-1.31).
Conclusions: We identified major differences in smoking initiation patterns among EU countries, which may warrant different approaches in the prevention of tobacco use.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/eurpub/ckv068 | DOI Listing |
Ther Adv Drug Saf
January 2025
Pharmacology Department, School of Medicine, University of Valladolid, Valladolid, Spain.
In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating and remitting depressive symptoms, with sustained benefits observed for nearly 4.5 years.
View Article and Find Full Text PDFSleep Med
January 2025
School of Exercise and Health, Shanghai University of Sport, Shanghai, China; Shanghai Frontiers Science Research Base of Exercise and Metabolic Health, Shanghai University of Sport, Shanghai, China; Key Laboratory of Exercise and Health Sciences, Shanghai University of Sport, Shanghai, China. Electronic address:
Introduction: Delayed sleep-wake phase disorder(DSWPD)is a serious threat to the physical and mental health. There are some problems with current clinical treatment methods, and exercise is an alternative to chronotherapy. Therefore, we aimed to study the effects of two different exercise methods, aerobic and resistance, on sleep, melatonin, inflammatory factors and mood in college students with DSWPD.
View Article and Find Full Text PDFFront Public Health
January 2025
Department of Nursing, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Introduction: Osteoarthritis (OA) is a prevalent and debilitating disorder that affects the joints and has a complex array of causes. While sedentary behavior (SB) and physical activity (PA) have been implicated in OA risk, the relationship between these factors and OA development remains unclear. This study investigates the correlation and potential causality between SB, PA, and OA using both cross-sectional and Mendelian randomization (MR) analysis.
View Article and Find Full Text PDFExpert Opin Drug Saf
January 2025
Department of Pharmacy, Nanchuan Hospital of Chongqing Medical University, Chongqing, China.
Background: Pimavanserin is a new non-dopamine neurotransmitter antipsychotic drug. This study aimed to conduct a post-marketing pharmacovigilance study of pimavanserin, through data mining technology using the FDA Adverse Event Reporting System (FAERS) database.
Research Design And Methods: We analyzed adverse event reports for patients using pimavanserin.
J Oncol Pharm Pract
January 2025
Department of Oral and Maxillofacial Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Background: Medication-related osteonecrosis of the jaw (MRONJ) is a rare but potentially severe condition that significantly affects the quality of life of patients with cancer. This study evaluated MRONJ in patients with cancer treated with zoledronic acid (ZOA) and denosumab (Dmab).
Methods: The survey investigated patients who were diagnosed with MRONJ at the Department of Oral and Maxillofacial Surgery after receiving either ZOA or Dmab at the Saitama Medical Center, Saitama Medical University, between April 1, 2022, and March 31, 2023.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!